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Abstract
Hepatitis C virus (HCV) genotype 3 presents a high level of both baseline and acquired resistance to direct- acting antivirals 
(DAAs), particularly those targeting the NS5A protein. To understand this resistance we studied a cohort of Brazilian patients 
treated with the NS5A DAA, daclatasvir and the nucleoside analogue, sofosbuvir. We observed a novel substitution at NS5A 
amino acid residue 98 [serine to glycine (S98G)] in patients who relapsed post- treatment. The efect of this substitution on 
both replication itness and resistance to DAAs was evaluated using two genotype 3 subgenomic replicons. S98G had a modest 
efect on replication, but in combination with the previously characterized resistance- associated substitution (RAS), Y93H, 
resulted in a signiicant increase in daclatasvir resistance. This result suggests that combinations of substitutions may drive a 
high level of DAA resistance and provide some clues to the mechanism of action of the NS5A- targeting DAAs.
INTRODUCTION
Hepatitis C virus (HCV) currently infects an estimated total 
of 70 million individuals worldwide. In 85 % of cases infection 
leads to chronic liver disease: ibrosis, cirrhosis and hepato-
cellular carcinoma (HCC). HCV has a positive- strand RNA 
genome and is the most variable human virus, classiied into 
seven genotypes (GTs), exhibiting >30 % nucleotide sequence 
divergence, with each GT being further divided into subtypes 
[1]. GT3 is the second most common GT (ater GT1) and 
accounts for 30 % of global HCV cases [2, 3]. he variability 
of the virus results from a lack of proofreading activity of 
the viral RNA- dependent RNA polymerase (NS5B) and 
importantly enables the emergence of mutations that can 
lead to evasion of both the immune response and antiviral 
treatments.
he development of direct- acting antivirals (DAAs) has revo-
lutionized the treatment of HCV infection. In Brazil, since 
2015, the administration of pegylated interferon-α and riba-
virin has only occurred in a few cases, and the irst generation 
of DAAs (telaprevir and boceprevir) has been discontinued. A 
second generation of DAAs is currently in use and comprises 
simeprevir (NS3 protease inhibitor), daclatasvir (NS5A 
inhibitor) and sofosbuvir (NS5B inhibitor). However, despite 
the high eiciency of this therapy, resistance is still reported 
in approximately 10 % of the patients, depending on the 
viral genotype and the disease progression level. Resistance 
is invariably linked to the presence of resistance- associated 
substitutions (RASs). Generally, these substitutions can be 
found easily and in high frequency ater treatment failure, 
but in some cases they can be detected pre- treatment and 
rapidly increase in frequency due to the selective pressure of 
DAAs. Since the circulation of these pre- existing substitutions 
can impact on the eicacy of antiviral treatment, studying the 
phenotype of these substitutions with regard to DAA resist-
ance and viral itness is important to understand DAA failure.
Among all HCV genotypes, GT3 exhibits the greatest resist-
ance to DAA therapy, with lower response rates compared to 
other genotypes. his response is even lower in patients with 
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advanced liver disease, such as cirrhosis [3]. GT3 is the second 
most prevalent genotype in Brazil, being responsible for 
approximately 24 % of the infections, and is thus an important 
public health problem [4]. In this regard, this study focused 
on resistance to the NS5A- targeting DAA daclatasvir (DCV) 
with a view to characterizing the substitutions associated with 
treatment failure in GT3- infected patients. We observed a 
novel substitution in NS5A, serine 98 to glycine (S98G), 
that was present at high frequency in samples from relapsed 
patients compared to those who exhibited a sustained viro-
logical response (SVR). We characterized the phenotype of 
this substitution in the context of both replication itness and 
resistance to DAAs, using two subgenomic replicon (SGR) 
systems recently developed for GT3.
METHODS
Clinical samples
he population in this study consists a cohort of HCV GT3- 
infected patients under treatment with the NS5A inhibitor 
daclatasvir (DCV) and the NS5B inhibitor sofosbuvir (SOF). 
Serum samples from these patients were collected at Ribeirão 
Preto Medical School, University of São Paulo, Brazil. he 
samples were collected at two diferent time points, before 
and ater treatment, where treatment response was assessed. 
Individuals who did not present an SVR ater treatment were 
considered to be non- responders, while those in whom viral 
load was detected 24 weeks ater treatment end were consid-
ered relapsers. Individuals whose viral load was not detected 
during treatment and at this last time point were classiied 
as responders.
Molecular analysis
RNA was extracted from serum using TRIzol according 
to the manufacturer’s instructions (hermo Fisher Scien-
tiic), followed by cDNA synthesis using the High- Capacity 
cDNA Reverse Transcription kit (Applied Biosystems). 
Considering that DCV interaction with NS5A occurs in 
domain I, likely between amino acids 28 and 93 [5], we 
ampliied and sequenced the irst 300 nucleotides of the 
NS5A coding region. Ampliication of the target region was 
performed by nested PCR using Long PCR Enzyme Mix 
(hermo Fisher Scientiic) and speciic primers (sequences 
available upon request). Sequencing was performed using 
the Sanger method with BigDye Terminator v.3.1 (Applied 
Biosystems) using the same primers as the second PCR. 
Readings were performed in a 3130xl Genetic Analyzer 
(Applied Biosystems).
Cell culture
Huh7.5 cells, a human hepatocellular carcinoma cell line, 
were cultured in Dulbecco’s modiied Eagle’s medium 
(DMEM) supplemented with 10 % foetal bovine serum (FBS), 
100 IU ml−1 penicillin and 100 µg ml−1 streptomycin. Cells 
were incubated at 37 °C and 5 % CO
2
.
SGR constructs
he in vitro approaches in this study were based on two GT3a 
SGRs from diferent isolates, SGR- luc- S52 [6], derived from 
S52/SG- neo [7], and SGR- luc- DBN3a [8], derived from the 
DBN3a infectious clone [9]. As a negative control, we used the 
replication defective constructs with inactivating mutations 
in the RNA- dependent RNA polymerase, NS5B: GDD→GNN. 
his, and the other mutations, were introduced using the Q5 
Site- Directed Mutagenesis kit (New England Biosciences).
SGR replication assays
SGR RNA was produced by in vitro transcription and 
electroporated in Huh7.5 cells with the Gene Pulser Xcell 
Electroporation System (Bio- Rad), using the square wave 
protocol (260V, 25 ms, 1 pulse and 4 mm cuvette). For each 
electroporation, 2×106 cells were added to the cuvette and, 
ater the procedure, 104 cells were seeded in each well, in a 
96- well white plate. Cells were lysed using Passive Lysis Bufer 
(PLB) (Promega) and replication was analysed by measuring 
luciferase activity using the Luciferase Assay System kit 
(Promega). he assay was analysed at 24, 72 and 96 h post- 
electroporation (p.e.) for S52, and 24, 48 and 72 h p.e. for 
DBN3a. his diference in incubation period is due to the 
more eicient replication of DBN3a [9]. For the DAA assays, 
at 4 h p.e. DAAs were added to the media at the appropriate 
concentration ranges and incubated for 96 (S52) or 72 h 
(DBN3a). All assays were performed in triplicate and three 
independent assays were performed.
Statistical analysis
Data were analysed using GraphPad Prism 5 sotware. he 
mean and standard deviation were determined, and all statis-
tical analyses were performed using the analysis of variance 
(ANOVA) test and Dunnett’s multiple comparison test, 
considering P<0.05 as signiicant.
RESULTS
Identification of a novel substitution in NS5A from 
patients who relapsed after DAA therapy
his study analysed a cohort of 82 patients infected with HCV 
genotype 3 who were treated with a combination of sofosbuvir 
(SOF: NS5B inhibitor) and daclatasvir (DCV: NS5A inhibitor) 
for a period of 12 weeks. Serum samples from these patients 
were collected at Ribeirão Preto Medical School, University 
of São Paulo (USP), Brazil. he SVR rate for this cohort was 
92.7 %. Although all of the patients responded to therapy, six 
of them then relapsed ater the end of treatment. In an attempt 
to understand the molecular basis for relapse, we performed 
Sanger sequence analysis of NS5A domain I (corresponding 
to amino acids 28–100) both pre- and post- treatment. We 
detected a number of substitutions within the NS5A domain 
I coding sequence when compared to the consensus genotype 
3 (NZL1) (see Table 1), but the most prevalent was S98G, 
which was present in 14.45 % of all pre- treatment samples. 
What was more interesting, however, was that this substitu-
tion was present in 66.6 % of the patients who subsequently 
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relapsed, compared to 9.63 % of responders (Fig. 1). In the 
post- treatment samples, S98G was present in the relapsed 
patients at a frequency of 50 % (Table 2, Fig. 1). A comparison 
with 2915 genotype 3 isolates from diferent geographical 
regions showed that S98G is present at a frequency of 14.5 %, 
corresponding with our pre- treatment frequency. Of note, 
as expected, other previously described substitutions (A30K, 
A62T and Y93H) were also present at higher frequency in 
the post- treatment samples from the six relapsed patients 
(Table 2), but we focused on S98G, as it had not previously 
been associated with DAA resistance. We were intrigued that 
the presence of S98G in pre- treatment samples seemed to 
correlate with relapse ater DCV treatment and we therefore 
set out to analyse the efect of this substitution on viral itness 
and DAA sensitivity in vitro.
In vitro replication phenotype of S98G
To evaluate the itness impact of this substitution during viral 
genome replication, site- directed mutagenesis was performed 
to generate S98G derivatives of two diferent genotype 3 SGRs: 
S52 and DBN3a. he SGR- luc- S52 was described previously 
[6] and the DBN3a SGR was derived from the DBN3acc infec-
tious clone [9] and has been described elsewhere [8]. Both 
SGRs contained a modiied irely luciferase reporter with 
an engineered low frequency of CpG/UpA dinucleotides; we 
[6] and others [10] have previously shown that this enhances 
the replication of GT3 SGRs through an as yet undeined 
mechanism.
Huh7.5 cells were electroporated with SGR- luc- S52 or SGR- 
luc- DBN3a, including the corresponding polymerase- inactive 
GNN mutants as negative controls, and luciferase levels were 
assayed in lysates harvested between 4–96 h p.e. to measure 
genome replication. For both SGRs, the S98G substitution 
was tolerated and allowed a similar replication level to the 
original. However, for S52 there was some evidence that S98G 
resulted in a modest enhancement of replication. As expected, 
S52 replicated poorly (Fig. 2a) and, although the input value 
(4 h) for S98G was signiicantly lower than the original, by 
96 h both S98G and the original exhibited the same luciferase 
value, suggesting that S98G was able to replicate more ei-
ciently. his was conirmed by the normalized data (normal-
ized to the 4 h value) (Fig. 2b), showing that S98G did indeed 
replicate at a level that was statistically signiicantly higher 
than wild- type. In contrast, the DBN3a SGR replicated more 
eiciently than S52, and in this case all values for both S98G 
and the original were indistinguishable. We conclude that 
S98G can confer a modest increase in replicative itness in 
HCV GT3a, although, in the context of an already eiciently 
replicating SGR, this enhancement was not observed.
S98G resistance phenotype against DAAs
As S98G was associated with relapsing patients, we investi-
gated the efect of this substitution on the response to two 
NS5A inhibitors: DCV (used in the clinical study) and 
velpatasvir (VEL) a third- generation DAA with potent pan- 
genotypic activity that was not available in Brazil whilst this 
patient cohort was being treated. Huh7.5 cells electroporated 
with SGRs were treated with DAAs at diferent concentrations 
Table 1. Substitutions identiied in this study; those in bold were 
previously unidentiied
Substitution Pre- treatment frequency Post- treatment 
frequency
D3N 2.4 % (2/82) 16.6 % (1/6)
A75V 6.1 % (5/82) 16.6 % (1/6)
T79M 6.1 % (5/82) 16.6 % (1/6)
T94F 0 % 16.6 % (1/6)
S98G 14.45 % (12/82) 50 % (3/6)
A30K 6.1 % (5/82) 33.3 % (2/6)
A62T 24.4 % (20/82) 50 % (3/6)
Y93H 0 % 66.6 % (4/6)
Fig. 1. Frequency of S98G in the studied population.
Table 2. Presence of substitutions in the samples from patients who 
relapsed therapy
Substitution
Post- treatment sample number* A30K A62T Y93H S98G
P11 − − + +
P45 − − + −
P112 + + − −
P175 − + + +
P189 + + − +
P192 − − + −
*Numbers are identiication codes from a biobank of HCV samples 
held at São Paulo State University.
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to determine the efective concentration 50 % (EC
50
). As a 
control we also determined the EC
50
 for the NS5B inhibitor, 
SOF, a nucleoside analogue. For S52, the S98G substitution 
did have a modest efect on the DCV EC
50
 with an increase 
from 11.5 to 20 pM (Fig. 3a), although it is unlikely that this 
would contribute to clinical resistance. S98G had no efect on 
the VEL or SOF EC
50
 values for S52 (Fig. 3b, c). In contrast, 
for DBN3a (Fig. 4), the S98G substitution had no efect on 
the response to any of the DAAs tested.
S98G phenotype in the presence of Y93H
his result was somewhat surprising and did not explain why 
S98G was strongly associated with the relapsing phenotype, 
as it appeared to confer very little selective advantage, either 
in the context of replicative itness or DAA resistance. We 
reasoned that S98G might therefore confer some advantage 
when combined with other substitutions. To address this, we 
focused our attention on the well- characterized RAS, Y93H. 
We had previously demonstrated that, in our hands, Y93H 
resulted in a 71 000- fold increase in the DCV EC
50
 for the 
S52 SGR [6].
Y93H was not detected in pre- treatment samples, with 
the proviso that analysis was by Sanger sequencing, so it is 
possible that Y93H was present as a minor variant below the 
frequency of detection. In contrast, it was detected in 66.6 % 
(4/6) of the post- treatment samples from the relapsed patients 
and, in two of these, this substitution occurred in conjunc-
tion with S98G. To test the potential phenotype of S98G in 
Fig. 2. Replication phenotype of S98G. (a) S52 SGR RNAs (original, S98G 
and NS5B GNN) were electroporated into Huh7.5 cells and harvested 
at the indicated times for the luciferase assay. (b) S52 SGR replication 
values were normalized to the 4 h p.e. values (corresponding to 
translation of input RNA). P<0.01. (c) DBN3a SGR RNAs (original, S98G 
and NS5B GNN) were electroporated into Huh7.5 cells and harvested at 
the indicated times for luciferase assay.
Fig. 3. DAA resistance phenotype of S98G. S52 SGR RNAs (original or 
S98G) were electroporated into Huh7.5 cells, treated with DCV (a), VEL 
(b) or SOF (c) at the indicated concentrations for 96 h prior to harvest for 
luciferase assay. Values were normalized to the no- DAA controls. EC
50
 
values for original and S98G are indicated on the right.
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the context of Y93H, we generated SGR- luc- DBN3a deriva-
tives with either Y93H alone, or the combination of Y93H/
S98G. For this we focused on DBN3a as the replication levels 
were higher than S52, making it easier to identify any subtle 
diferences in replication. Huh7.5 cells were electroporated 
with SGRs, including the polymerase- inactive GNN mutant 
as negative control, and harvested over a 72 h time period 
(Fig. 5). he data show that both Y93H and Y93H/S98G repli-
cated to a similar level as the original. Although the luciferase 
values throughout for both were slightly lower than those 
for the original, this is most likely due to lower transfection 
eiciency, as evidenced by the 4 h time point. Importantly, 
the rate of replication for all three SGRs between 24–72 h was 
indistinguishable, clearly demonstrating that neither substitu-
tion impacted on replication itness.
We therefore evaluated the efect of Y93H and Y93H/S98G 
on the response of SGR- luc- DBN3a to DCV, VEL and SOF. 
As expected, Y93H resulted in a dramatic increase in the 
resistance of SGR- luc- DBN3a to DCV, increasing the EC
50
 
from 16 pM to 194 nM (Fig. 6a). Reassuringly, the presence 
of S98G further increased the EC
50
 to 455 nM. he DBN3a 
SGR was highly sensitive to VEL, and again Y93H resulted in 
an increase of the EC
50
 from 0.014 pM to 0.195 nM (Fig. 6b). 
However, in this case S98G did not result in the acquisition 
of further resistance. Neither Y93H nor the combination of 
Y93H/S98G resulted in resistance to SOF compared to the 
original (Fig. 6c). Although the efect of S98G was modest, it 
did provide an explanation for the selection of S98G in samples 
from patients who relapsed following DCV treatment.
DISCUSSION
In this study we identify a novel substitution, S98G, in NS5A 
of GT3a- infected patients who relapsed following DAA treat-
ment. he strict deinition of an RAS is a substitution from the 
consensus that conferred reduced sensitivity of a virus to one 
or more antiviral drugs. he data presented here demonstrate 
that this is not the case for S98G and thus it cannot be specii-
cally deined as an RAS. However, our data clearly show that 
in combination with the well- characterized RAS Y93H, it can 
enhance resistance to DCV.
he frequency of S98G was signiicantly higher in relapsed 
patients post- therapy compared to pre- treatment and we 
considered that it might be contributing directly to treatment 
failure. If this was the case, S98G would need to maintain 
replicative itness and result in an increase in DCV EC
50
. 
To evaluate whether this was the case, we investigated the 
phenotype of the corresponding mutation in the context of 
two GT3a SGRs derived from the S52 [7] and DBN3a [9] 
infectious clones. his analysis revealed that S98G had no 
deleterious efect on the replicative capacity of either SGR; 
indeed, in the context of the poorly replicating S52 SGR, it 
exhibited a modest enhancement of replication (Fig. 2a, b). 
hus, there would be no selective disadvantage of S98G, and 
S98G could persist in a viral population, as it had no replica-
tive defect.
S98G alone had little or no efect on the EC
50
 for DCV in the 
context of either SGR (Figs 3 and 4). Although there was a 
modest increase in the S52 EC
50
 (from 11.5 to 20 pM), this 
Fig. 4. DAA resistance phenotype of S98G. DBN3a SGR RNAs (original or 
S98G) were electroporated into Huh7.5 cells, treated with DCV (a), VEL 
(b) or SOF (c) at the indicated concentrations for 72 h prior to harvest for 
luciferase assay. Values were normalized to the no- DAA controls. EC
50
 
values for original and S98G are indicated on the right.
Fig. 5. Replication phenotype of S98G in combination with Y93H. 
DBN3a SGR RNAs (original, Y93H, Y93H/S98G and NS5B GNN) were 
electroporated into Huh7.5 cells and harvested at the indicated times 
for luciferase assay.
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would not be expected to have a clinically signiicant efect. 
he plasma concentration of DCV in the 24 h period following 
a single daily dose of 60 mg was between 270–2700 nM [11]. 
Although modelling analysis suggests that tissue concentra-
tions are 10- fold lower [12], this would still give a concentra-
tion of between 27–270 nM in the liver. his did not explain 
the apparent selection of S98G in relapsed patients. We there-
fore considered that S98G might act additively, or synergisti-
cally, with other substitutions to further increase EC
50
 values. 
An obvious candidate was Y93H, which was also observed in 
the relapsed patient post- treatment samples. To test this, we 
analysed the phenotype of S98G when combined with Y93H 
in the context of the DBN3a SGR and compared this with 
either the original or Y93H. SGR- luc- DBN3a Y93H or Y93H/
S98G replicated as well as the original (Fig. 5), indicating that 
the combination of these two substitutions did not adversely 
afect replicative capacity and could therefore persist in a viral 
population. Reassuringly, compared to Y93H, the combined 
Y93H/S98G SGR exhibited a further increase in DCV EC
50
, 
from 194 to 455 nM (Fig. 6). Although this is only a ~twofold 
increase, we believe that it is potentially clinically signiicant 
– if the maximal DCV concentration in the liver is 270 nM, 
then this level of DCV would be predicted to inhibit both the 
original and Y93H, but would be less efective against Y93H/
S98G. Although by necessity speculative, this conclusion does 
provide some indirect evidence for a selective advantage of the 
Y93H/S98G combination during DCV therapy. In contrast, 
S98G had no efect on the EC
50
 for VEL – both Y93H and 
Y93H/S98G exhibited a similar EC
50
 for this DAA (Fig. 6). 
his has implications for the choice of DAA regime – patients 
with baseline Y93H/S98G RAS should be treated with a DAA 
combination that contains VEL, not DCV. Indeed, this is now 
the case in many countries, including Brazil, so the presence of 
S98G may have less clinical impact than previously expected. 
As the two substitutions are only 15 nucleotides apart, it 
should be relatively easy to identify linkage via either next- 
generation or conventional Sanger sequencing approaches. 
Interestingly, S98G was observed in a subset of the relapsed 
patients in the absence of Y93H (Table 1), suggesting that it 
might also contribute to resistance in cooperation with other 
previously deined RASs (e.g. A30K or A62T).
So, how might S98G cooperate with Y93H to drive high- level 
resistance to DCV? Even if not currently of clinical signiicance, 
could S98G provide some insight into the obscure mode of 
action of the NS5A- targeting DAAs? To address this we mapped 
the two substitutions onto the three- dimensional structure of 
domain I of genotype 1b NS5A [13, 14] (Fig. 7). Although close 
to each other in the primary amino acid sequence (Fig. 7a), the 
two residues are not proximal within the structure. In particular, 
residue 93 is surface- exposed, whereas residue 98 is partially 
buried (Fig. 7Bb). However, it is still plausible that both residues 
form key contact points for DCV binding, or, alternatively S98G 
might have an allosteric efect on the structure of NS5A. he 
other implication of the data is that the potential interaction of 
VEL with NS5A is subtly diferent than that of DCV and does 
not involve residue 98. VEL is clearly a more potent DAA in 
comparison to DCV, but is equally afected by Y93H (Fig. 6), 
and so it is likely that VEL contacts other residues within NS5A, 
perhaps residues that are more functionally constrained and 
therefore cannot mutate to confer resistance.
Our data are consistent with the notion that the resistance 
of HCV GT3 to NS5A- targeting DAAs is driven by multiple 
Fig. 6. DAA resistance phenotype of S98G in combination with Y93H. 
DBN3a SGR RNAs (original, Y93H or Y93H/S98G) were electroporated 
into Huh7.5 cells, treated with DCV (a), VEL (b) or SOF (c) at the indicated 
concentrations for 72 h prior to harvest for luciferase assay. Values 
were normalized to the no DAA controls. EC
50
 values for original and 
S98G are indicated on the right.
Fig. 7. NS5A domain I monomer tertiary structure and surface 
representation, showing the localization of Y93 (in blue) and S98 (in 
red).
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substitutions and varies with respect to the speciic DAA being 
administered to the patient. Consideration must be given to 
baseline substitutions when deciding on clinical approaches. 
he identiication of novel substitutions such as S98G may 
contribute to our understanding of the molecular mechanisms 
of, and resistance to, NS5A- targeted DAAs, and may also be a 
useful tool to investigate NS5A functions in the virus lifecycle. 
In this context, it will be intriguing to study the phenotype of 
S98G in the context of infectious virus, particularly in light 
of our previous observation that NS5A domain I plays a role 
in virus assembly [15]. Such experiments are planned in our 
laboratory for when work can recommence following the coro-
navirus disease 2019 (COVID-19) lockdown.
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